The FOSS well apparently never runs dry—here’s the next round of this roundup.
Solstice Advanced Materials to acquire Element Solutions in a cash-and-stock deal valued at ~$14.5B, including the assumption ...
Polypharmacy in patients with cardiovascular disease occurs frequently across the age spectrum and can lead to inappropriate prescribing and adverse outcomes. Despite polypharmacy being a known ...